349 related articles for article (PubMed ID: 23316055)
1. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
2. Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.
Feng Y; Chelico L
J Biol Chem; 2011 Apr; 286(13):11415-26. PubMed ID: 21300806
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
5. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
Ara A; Love RP; Chelico L
PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G.
Sugiyama R; Nishitsuji H; Furukawa A; Katahira M; Habu Y; Takeuchi H; Ryo A; Takaku H
J Biol Chem; 2011 Mar; 286(12):10051-7. PubMed ID: 21228271
[TBL] [Abstract][Full Text] [Related]
8. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
Jäger S; Kim DY; Hultquist JF; Shindo K; LaRue RS; Kwon E; Li M; Anderson BD; Yen L; Stanley D; Mahon C; Kane J; Franks-Skiba K; Cimermancic P; Burlingame A; Sali A; Craik CS; Harris RS; Gross JD; Krogan NJ
Nature; 2011 Dec; 481(7381):371-5. PubMed ID: 22190037
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
10. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
11. DNAJB8 facilitates autophagic-lysosomal degradation of viral Vif protein and restricts HIV-1 virion infectivity by rescuing APOBEC3G expression in host cells.
Chand K; Barman MK; Ghosh P; Mitra D
FASEB J; 2023 Mar; 37(3):e22793. PubMed ID: 36723955
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
Sadler HA; Stenglein MD; Harris RS; Mansky LM
J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
[TBL] [Abstract][Full Text] [Related]
13. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
Li L; Liang D; Li JY; Zhao RY
Retrovirology; 2008 Aug; 5():72. PubMed ID: 18680593
[TBL] [Abstract][Full Text] [Related]
15. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
16. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
Green LA; Liu Y; He JJ
J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
